Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-F3-C25
- Development stage
- Unknown
- Lead developer
- University of Alabama at Birmingham
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
**212Pb-F3-C25** is a TCMC-chelated, lead-212-labeled anti-idiotypic monoclonal antibody based on F3-C25. It has been used as an irrelevant isotype-matched control radioimmunoconjugate in preclinical mouse studies of ovarian cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Lead-212 serves as an in vivo source of cytotoxic alpha-particle radiation through its decay chain; unlike the comparator antibodies used in these studies, F3-C25 does not target the tumor-associated antigens B7-H3 or CSPG4. It is a research-stage control radiopharmaceutical rather than a clinically developed therapeutic program. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5817013/))
- Other names
- 212Pb-mAb F3-C25Pb-212-F3-C25Pb212-F3-C25Pb 212-F3-C25
02
Targets
DNAMHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on 212Pb-F3-C25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-F3-C25.